VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NUTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NUTXNutex Health, Inc.
$174.51$1.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksNUTXFinancials

Nutex Health, Inc. (NUTX) Income Statement

13Y historyFree accessUpdated daily

Revenue of $217.6M in 2026Q3 reflects a sharp -18.7% year-over-year decline, while net margin compressed to 18.5% from 31.2% in the prior quarter, suggesting the recent profit cushion is narrowing faster than headline results imply.

Income StatementBalance SheetCash FlowRatios

NUTX Income Statement

Annual statement

NUTX Income Statement

Nutex Health, Inc. (NUTX) annual income statement — 13-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'11Dec'10
Sales/Revenue796.53M875.26M479.95M247.65M219.29M331.53M274.03M97.06M1.37M23.17K002.55M1.27M
Revenue Growth %-18.82%82.36%93.8%12.93%-33.85%20.98%182.34%7000.03%5800.87%---100%101.26%-
Cost of Goods Sold415.86M430.98M283.69M212.87M203.87M152.25M116.42M40.17M508.16K564.37K4736621.53M783.17K
COGS % of Revenue-49.24%59.11%85.96%92.97%45.92%42.49%41.38%37.17%2436.19%--60.01%61.84%
Gross Profit380.67M444.28M196.26M34.77M15.42M179.28M157.61M56.89M858.83K-541.2K-473-6621.02M483.19K
Gross Margin %47.79%50.76%40.89%14.04%7.03%54.08%57.51%58.62%62.83%-2336.19%--39.99%38.16%
Gross Profit Growth %-126.37%464.39%125.49%-91.4%13.75%177.03%6524.14%258.69%-28.55%-100.06%110.92%-
Operating Expenses69.67M168.66M65.64M66.55M422.02M9.02M4.43M22.18M1.7M1.81M448.12K532.33K1.86M1.83M
OpEx % of Revenue-19.27%13.68%26.87%192.44%2.72%1.62%22.85%124.3%7828.82%--73.13%144.46%
Selling, General & Admin68.8M168.66M58.56M36.07M20M5.46M4.43M59.87M1.16M1.81M448.12K532.33K1.86M1.83M
SG&A % of Revenue-19.27%12.2%14.56%9.12%1.65%1.62%61.68%85.13%7828.82%--73.13%144.46%
Research & Development00000285.88K00545.22K25.64K0000
R&D % of Revenue-----0.09%--39.88%110.7%----
Other Operating Expenses-1000K07.08M30.48M402.02M3.27M0-37.69M-9.76K-25.64K0000
Operating Income311M275.63M130.62M-31.77M-406.6M170.26M153.17M34.71M-840.4K-2.35M-448.6K-532.99K-844.58K-1.35M
Operating Margin %39.04%31.49%27.22%-12.83%-185.41%51.36%55.9%35.76%-61.48%-10165%---33.14%-106.31%
Operating Income Growth %-111.01%511.1%92.19%-338.8%11.16%341.29%4230.27%64.31%-424.93%15.83%36.89%37.26%-
EBITDA332.62M296.15M149.59M-14.18M-393.47M177.93M159.07M37.19M-839.88K-1.82M-448.13K-532.33K-844.58K-1.35M
EBITDA Margin %41.76%33.84%31.17%-5.73%-179.42%53.67%58.05%38.32%-61.44%-7855.48%---33.14%-106.31%
EBITDA Growth %-10.37%97.97%1154.79%96.4%-321.14%11.85%327.75%4527.83%53.85%-306.09%15.82%36.97%37.26%-
D&A (Non-Cash Add-back)21.62M20.53M18.97M17.59M13.13M7.66M5.9M2.48M522535.02K47366200
EBIT311.32M267.01M129.68M-32.17M-407.16M175.69M152.17M35.62M-840.33K-5.64M-448.48K-532.98K-815.44K-1.34M
Net Interest Income-19.19M-22.23M-19.93M-16.32M-12.49M-6.2M-6.43M-3.53M-109.73K-367.35K-2.46K-3.14K00
Interest Income00000000680114429.14K8.27K
Interest Expense19.19M22.23M19.93M16.32M12.49M6.2M6.43M3.53M109.8K367.35K2.58K3.15K00
Other Income/Expense-18.92M-30.84M-20.87M-16.72M-13.05M-773.88K-7.43M-2.62M-109.73K-3.65M-2.46K-3.14K29.14K8.27K
Pretax Income292.08M244.78M109.75M-48.49M-419.65M169.49M145.74M32.09M-950.13K-6.01M-451.06K-536.13K-815.44K-1.34M
Pretax Margin %36.67%27.97%22.87%-19.58%-191.36%51.12%53.18%33.06%-69.5%-25932.29%---31.99%-105.65%
Income Tax59.05M64.42M14.48M-5.07M13.09M965.73K181.34K00000-432.05K-1.5M
Effective Tax Rate %20.22%26.32%13.19%10.45%-3.12%0.57%0.12%0%0%0%0%0%52.98%111.82%
Net Income164.71M70.79M52.18M-45.79M-424.78M132.59M105.97M20.92M-2.81M582.06K-7.43M83.81K-383.39K158.14K
Net Margin %20.68%8.09%10.87%-18.49%-193.7%39.99%38.67%21.56%-205.87%2512.57%---15.04%12.49%
Net Income Growth %44.4%35.67%213.96%89.22%-420.36%25.12%406.47%843.47%-583.5%107.83%-8968.07%121.86%-342.44%-
Net Income (Continuing)233.03M180.36M95.27M-43.42M-432.74M168.53M145.56M32.09M-950.13K-6.01M-451.06K-536.13K-546.98K-839.17K
Discontinued Operations0000000000-6.98M000
Minority Interest105.34M93.99M55.55M17.65M24.46M76.93M61.56M22.53M000000
EPS (Diluted)23.3910.489.71-10.39-100.3633.5524.694.88-0.02-0.07-3.600.04-0.320.13
EPS Growth %23.04%7.93%193.46%89.65%-399.14%35.88%405.94%24500%71.43%98.06%-8967%112.69%-346.15%-
EPS (Basic)-11.1310.23-10.39-100.5033.5524.694.88-0.02-0.07-3.600.04-0.320.13
Diluted Shares Outstanding7.04M6.76M5.1M4.41M4.23M3.95M4.29M4.14M7.18M4.18M2.07M2.07M1.2M1.2M
Basic Shares Outstanding6.85M6.36M5.1M4.41M4.23M3.95M4.29M4.14M7.18M4.18M2.07M2.07M1.2M1.2M
Dividend Payout Ratio-104.93%12.34%--108.86%55.72%90.34%------

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Volatile Net Margin Compression

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Growth Decelerating From Peak Levels

Based on Nutex's reported quarterly figures, revenue reached $217.6M in 2026Q3 with year-over-year growth of -18.7%, following a run of mixed quarterly momentum that suggests the earlier surge is cooling rather than compounding.

The reported quarterly series shows revenue fluctuating between roughly $151.7M and $267.8M without a clean upward trend, which points to lumpy patient volumes or episodic revenue recognition rather than steady network expansion. The -18.7% year-over-year decline in the latest quarter, paired with a -13.6% decline in 2026Q2, warrants investigation into whether the earlier growth was partly driven by acquisitions or one-time collections. Investors should monitor whether revenue stabilizes near the $210M-$220M range that appears to be the recent baseline.

Gross Margin Volatility Undermines Pricing Stability

As reported in the quarterly financials, Nutex's gross margin swung from 30.4% in 2025Q4 to 67.0% in 2026Q2, a range that suggests the cost base or payer mix is not yet structurally anchored.

Such a wide gross margin band across adjacent quarters is more consistent with variable reimbursement timing, changes in payer mix, or cost classification shifts than with durable pricing power. The 46.7% latest-quarter gross margin sits well below the 67.0% peak, which may indicate that the higher-margin periods were not repeatable. Without disclosed detail on cost classification, the sustainability of the mid-range margin remains an open analytical question.

Operating Leverage Concentrated in Volume Peaks

According to reported figures, operating margin ranged from 13.8% to 57.8% across recent quarters, with SG&A remaining comparatively small at roughly $10M to $20M, implying that operating income is driven primarily by revenue and cost-of-service swings rather than overhead.

The low and relatively stable SG&A base indicates overhead efficiency, yet the large swings in operating income show that the fixed-cost structure of the facilities amplifies revenue variability. When revenue falls, operating income compresses sharply, as seen in the move from 57.8% to 35.4% operating margin. This pattern suggests high operating leverage that cuts both ways and warrants monitoring of facility utilization.

Wide Operating-to-Net Gap Raises Questions

Based on Nutex's reported figures, the 2026Q3 operating margin of 35.4% compares with a net margin of 18.5%, and a net margin of -7.3% in 2025Q2 against a 13.8% operating margin, a gap that appears driven by non-operating items.

The persistent difference between operating and net margins suggests material below-the-line charges such as interest, amortization, or other non-operating items, though the provided data does not itemize them. Stock-based compensation of $78.7M in 2025Q2 alongside a net loss is a notable data point that may indicate compensation-driven earnings distortion. Earnings quality therefore appears difficult to assess from headline figures alone and merits deeper review of the reconciliation between operating and net income.

Sustainability of the Recent Profit Window

The strongest challenge is that Nutex's 2026Q3 EPS of $5.71 follows a year-over-year decline of 26.4%, suggesting the recent profit cushion may be narrowing faster than the headline beat implies.

A bear case would emphasize that revenue has fallen 18.7% year over year while operating margin compressed from 48.7% to 35.4%, a combination that points to earnings power under pressure. The operating margin of 35.4% remains high relative to the 18.5% net margin, and a continued squeeze on reimbursement or a rise in labor costs could compress margins further from elevated levels. Investors should treat the single-quarter EPS beat with caution until revenue growth re-establishes a consistent direction.

NUTX — Frequently Asked Questions

Quick answers to the most common questions about buying NUTX stock.

What was Nutex Health, Inc.'s (NUTX) revenue in 2025?

For fiscal year 2025, Nutex Health, Inc. (NUTX) reported total revenue of $875.3M. This represents a 69016.0% increase compared to $1.3M in 2010.

Is Nutex Health, Inc. (NUTX) profitable?

Nutex Health, Inc. (NUTX) is profitable, generating $70.8M in net income for the fiscal year ending 2025 with a net profit margin of 8.1%.

What is Nutex Health, Inc.'s operating profit margin?

Nutex Health, Inc. (NUTX) reported an operating income of $275.6M, resulting in an operating profit margin of 31.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Nutex Health, Inc.'s gross profit and gross margin?

Nutex Health, Inc. (NUTX) generated $444.3M in gross profit for the year, representing a gross profit margin of 50.8%. This demonstrates the company's core pricing power and production efficiency.